VEGFA and squamous cell lung carcinoma: Squamous cell lung cancer accounts for about 25–30% of NSCLC.[1] Progress in the management of advanced lung squamous cell carcinoma (LSCC) has been lagged behind.[2] For example, pemetrexed monotherapy and platinum-based doublet chemotherapy was not approved in patients with squamous histology because of inferior efficacy.[3] Nonetheless, bevacizumab, the vascular endothelial growth factor (VEGF) inhibitor, was contraindicated in LSCC due to pulmonary hemorrhage [4–6].